Attached files
| file | filename |
|---|---|
| EX-10.22 - EX-10.22 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d22.htm |
| 10-K - 10-K - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231x10k.htm |
| EX-32.2 - EX-32.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex32d2.htm |
| EX-32.1 - EX-32.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex21d1.htm |
| EX-10.34 - EX-10.34 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d34.htm |
| EX-10.33 - EX-10.33 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d33.htm |
| EX-10.23 - EX-10.23 - Kiniksa Pharmaceuticals, Ltd. | knsa-20201231xex10d23.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (Nos. 333-231910, 333-248656 and 333-238585) and Forms S-8 (Nos. 333-225196 and 333-237589) of Kiniksa Pharmaceuticals, Ltd. of our report dated February 25, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 25, 2021